Clinical trial
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro…
NCT00149019 · Hadassah Medical Organization, Other · Withdrawn
Key facts
| NCT number | NCT00149019 |
|---|---|
| Title | Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies. |
| Official title | Innovative Approaches for Targeted Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies. |
| Lead sponsor | Hadassah Medical Organization, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Solid Tumors |
| Intervention type | Drug |
| Interventions | Cell therapy with bispecific antibodies |
| Enrollment | 12 |
| Start date | May 1, 2002 |
| Completion | Sep 1, 2005 |
| First posted | Sep 8, 2005 |
| Last update posted | Apr 8, 2011 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: